miR-202 inhibits the progression of human cervical cancer through inhibition of cyclin D1

Yuexiong Yi; Huirong Li; Qiongying Lv; Kejia Wu; Wenfen Zhang; Juan Zhang; Dingjun Zhu; Qing Liu; Wei Zhang

doi:10.18632/oncotarget.12499

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-202 inhibits the progression of human cervical cancer through inhibition of cyclin D1

Yuexiong Yi, Huirong Li, Qiongying Lv, Kejia Wu, Wenfen Zhang, Juan Zhang, Dingjun Zhu, Qing Liu and Wei Zhang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:72067-72075. https://doi.org/10.18632/oncotarget.12499

Metrics: PDF 2402 views | HTML 2110 views | ?

Abstract

Yuexiong Yi1, Huirong Li2, Qiongying Lv1, Kejia Wu1, Wenfen Zhang3, Juan Zhang4, Dingjun Zhu5, Qing Liu3, Wei Zhang1

1Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, P.R. China

2Department of Gynecology, Shandong Jiaohong Hospital, Jinan, Shandong 250031, P.R. China

3Department of Gynecology, The 5th Hospital of Jinan, Shandong 250031, P.R. China

4The First Department of Gynecology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan 430071, P.R. China

5Department of Gynecology, Shiyan Materal and Children Health Hospital, Shiyan 44200, P.R. China

Correspondence to:

Wei Zhang, email: [email protected]

Keywords: miR-202, cyclin D1, cervical cancer

Received: June 30, 2016 Accepted: September 28, 2016 Published: October 06, 2016

ABSTRACT

The human cervical cancer (CC) acts as the most common one of women tumors. However, the pathological changes and molecular alterations of CC are not clear. It has been reported that miR-202 takes part in the development and progression of different tumors. The present study aims to detect the expression of miR-202 in 100 cases of CC tissues and cells, and then we continued to investigate the potential mechanisms of miR-202 in CC cells. In this work, we found that the expression of miR-202 is obviously decreased in both CC cell lines and tissues, and negatively related with the expression of cyclin D1 in SiHa, HeLa and Caski cells. In-vitro assay revealed that the ectopic expression of miR-202 suppressed the proliferation, migration and invasion of SiHa and HeLa cells. Additionally, the over-expression of miR-202 extremely affected the expression of cyclin D1 protein. Notably, the over-expression of cyclin D1 in SiHa and HeLa cells with miR-202 mimics attenuated the inhibitory effects of miR-202 on cell proliferation, migration and invasion. In conclusion, our study identified that miR-202 plays an important role in regulating cell proliferation, migration and invasion of CC by directly targeting cyclin D1, thus miR-202 may represent a potential therapeutic target for patients with cervical cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12499

Publication Alerts

Research Papers:

miR-202 inhibits the progression of human cervical cancer through inhibition of cyclin D1

Abstract